Vol 27, No 3 (2020)
Technology note — Interventional cardiology
Published online: 2020-05-20

open access

Page views 1152
Article views/downloads 1079
Get Citation

Connect on Social Media

Connect on Social Media

Atrial flow regulator as a novel therapy for patients with chronic heart failure

Łukasz Lewicki12, Robert Sabiniewicz3, Janusz Siebert14, Marek Szołkiewicz2
Pubmed: 32436584
Cardiol J 2020;27(3):309-311.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Lam CSP, Voors AA, de Boer RA, et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018; 39(30): 2780–2792.
  2. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011; 32(6): 670–679.
  3. Ewert P, Berger F, Nagdyman N, et al. Masked left ventricular restriction in elderly patients with atrial septal defects: a contraindication for closure? Catheter Cardiovasc Interv. 2001; 52(2): 177–180.
  4. Bruch L, Winkelmann A, Sonntag S, et al. Fenestrated occluders for treatment of ASD in elderly patients with pulmonary hypertension and/or right heart failure. J Interv Cardiol. 2008; 21(1): 44–49.
  5. Ritzema J, Troughton R, Melton I, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation. 2010; 121(9): 1086–1095.
  6. Shah SJ, Feldman T, Ricciardi MJ, et al. One-Year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiol. 2018; 3(10): 968–977.
  7. Paitazoglou C, Özdemir R, Pfister R, et al. The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction. EuroIntervention. 2019; 15(5): 403–410.
  8. Dąbrowska-Kugacka A, Ciećwierz D, Żuk G, et al. Atrial flow regulator for severe drug resistant pulmonary arterial hypertension after congenital heart defect correction. Cardiol J. 2019; 26(1): 102–104.
  9. Janus M, Sławek-Szmyt S, Araszkiewicz A, et al. Atrial flow regulator as a bridge to lung transplantation in a young patient with drug-resistant idiopathic pulmonary arterial hypertension. Kardiol Pol. 2020 [Epub ahead of print].